• Molecular NameOmeprazole
  • SynonymOMEP; Omeprazol [INN-Spanish]; omeprazole; Omeprazole magnesium; Omeprazolum [INN-Latin]; OMP; OMZ
  • Weight345.423
  • Drugbank_IDDB00338
  • ACS_NO73590-58-6
  • Show 3D model
  • LogP (experiment)2.23
  • LogP (predicted, AB/LogP v2.0)2.44
  • pka4.0
  • LogD (pH=7, predicted)2.43
  • Solubility (experiment)0.131 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-3.95
  • LogSw (predicted, AB/LogsW2.0)0.26
  • Sw (mg/ml) (predicted, ACD/Labs)0.04
  • No.of HBond Donors1
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds5
  • TPSA96.31
  • StatusFDA approved
  • AdministrationOral, IV
  • PharmacologyA proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome.
  • Absorption_value80.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability47.0
  • Protein binding95.0
  • Volume of distribution (VD)0.27 to 0.45 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (CYP2C19, CYP3A4)
  • Half life0.5~3 h
  • Excretion80% Renal, 20% Faecal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, and dry mouth.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A